IDH1 and glioma: IER5 overexpression in glioma patients was correlated with advanced clinicopathological characteristics (advanced WHO grade, WT IDH status, a primary therapy outcome of CR, age ≤ 60 years, and 1p/19q codeletion), short survival time, as well as poor prognosis.